商业化培养基|奥浦迈-细胞培养基和端到端CDMO解决方案

OPM-293平台

化学成分确定的基础培养基与高性能补料

OPM-293 瞬时转染系统是化学成分确定的基础培养基与补料组合，专为高效率瞬时转染HEK293细胞株设计开发。该瞬时转染系统支持HEK293细胞的高密度悬浮培养及瞬转。我们针对该系统配备了详尽的使用手册及灵活专业的技术支持。

OPM-293 瞬时转染系统支持高效蛋白质表达，表达量达到克/每升的级别，并且能够应用于腺病毒、腺相关病毒和慢病毒的高效率增殖。此外，OPM-293系列细胞培养基易于放大培养规模，适用于孔板、试管、摇瓶、Wave和大型生物反应器并具有一致的性能。

产品特点：

化学成分确定，可提供TSE/BSE证明
广泛用于各种用途的 HEK293 高密度悬浮培养
与国际友商培养基相比，腺相关病毒（AAV）表达量增加12-84%，慢病毒（LV）表达量增加50%以上
细胞性能测试中表现出优异的一致性（批次内&批次间 RSD<5%）
双生产基地保障快速稳定供货
符合GMP标准的生产
灵活、专业、省心的售后服务

申请新品试用

产品信息表

产品名称	货号	剂型	规格	类型	SDS	描述
OPM-293 CD03 Medium	81070-001	液体	1000mL	化学成分确定培养基
OPM-293 CD03 DPM	91070-010	干粉	10L	化学成分确定培养基
OPM-293 CD03 DPM	91070-050	干粉	50L	化学成分确定培养基
OPM-293 CD05 Medium	81075-001	液体	1000mL	化学成分确定培养基
OPM-293 CD05 DPM	P688293	干粉	10L/50L/100L	化学成分确定培养基
OPM-CD Trans293	P82019	液体	1000mL	化学成分确定培养基
OPM-293 ProFeed	F081918	液体	100mL	无蛋白质补料
OPM-293 ProFeed DPM	C228293	干粉	10L	无蛋白质补料
OPM-293 ProFeed	F081918-001	液体	1000mL	无蛋白质补料

使用奥浦迈产品发表的文献

Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2
Nature. 2022 Dec;612(7941):748-757.
Specificity of TGF-β1 signal designated by LRRC33 and integrin αVβ8
Nat Commun. 2022 Aug 25;13(1):4988.
Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay
Int J Biol Macromol. 2023 Jan 31;226:780-792.

使用奥浦迈产品发表的文献

Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2
Nature. 2022 Dec;612(7941):748-757.
Specificity of TGF-β1 signal designated by LRRC33 and integrin αVβ8
Nat Commun. 2022 Aug 25;13(1):4988.
Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay
Int J Biol Macromol. 2023 Jan 31;226:780-792.
A novel and secure pseudovirus reporter system based assay for neutralizing and enhancing antibody assay against Marburg virus
Front Microbiol. 2022 Jun 9;13:927122.
Anti-Claudin18. 2-IL-21 fusion protein bifunctional molecule has more powerful anti-tumor effect and better safety
Int Immunopharmacol. 2022 Dec 28;115:109634.
Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
Sci Rep. 2022 Oct 26;12(1):18011.
Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2
Adv Sci (Weinh). 2022 May;9(15):e2200063.
Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells
Front Immunol. 2022 May 27;13:920467.
Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo
Front Oncol. 2022 May 12;12:857927.
Screening and Identification of a Novel Anti–Siglec-15 Human Antibody 3F1 and Relevant Antitumor Activity
Mol Pharmacol. 2022 Sep;102(3):161-171.
Endodomain truncation of the HIV-1 envelope protein improves the packaging efficiency of pseudoviruses
Virology. 2022 Sep;574:1-8.
Preclinical characterization of a Fab-like CD3/CLDN18. 2 XFab® bispecific antibody against solid tumors
Immunobiology. 2022 Sep 30;227(6):152283.
Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain
FEBS Open Bio. 2022 Sep;12(9):1644-1656.
Novel application of anti‐human Fc nanobody for screening high‐producing CHO cells for monoclonal antibody
Eng Life Sci. 2022 Aug 23;22(10):608-618.
ORF8 protein of SARS‐CoV‐2 reduces male fertility in mice
J Med Virol. 2022 Sep;94(9):4193-4205.
S373P Mutation of Spike Protein in SARS-CoV-2 Stabilizes Omicron
Biorxiv.2022 July 19.
Augmenting Neutralization breadth against Diverse HIV-1 by increasing the Ab-Ag interface on V2
Adv Sci (Weinh). 2022 Mar 23;e2200063.
Structures of Omicron spike complexes and implications for neutralizing antibody development
Cell Rep. 2022 May 3;39(5):110770.
Hemagglutinin‐based DNA vaccines containing trimeric self‐assembling nanoparticles confer protection against influenza
J Leukoc Biol. 2022 Jan 17.
Screening of Monoclonal Antibodies Targeting the Equine IgG1 Based on Single B Cell Antibodies Gene Amplification Technology
China Biotechnology. 2022, Vol. 42 Issue (4): 17-23.
Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine
Biorxiv.2022 May.
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates
Nat Commun. 2021 Mar 1;12(1):1346.
An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
Protein Cell. 2021 Sep 23;1-21.
Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD
Cell Rep. 2021 Feb 2;34(5):108699.
Closed-state inactivation and pore-blocker modulation mechanisms of human CaV2. 2
Cell Rep. 2021 Nov 2;37(5):109931.
N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2
Elife. 2021 Aug 20;10:e69091.
Structure and Function of the Refined C-Terminal Loop in Imidazole Glycerol Phosphate Dehydratase from Different Homologs
J Agric Food Chem. 2021 Nov 24;69(46):13871-13880.
Development of a tetravalent T-cell engaging bispecific antibody against glypican-3 for hepatocellular carcinoma
J Immunother. 2021 Apr 1;44(3):106-113.
Self-assembling nanoparticle vaccines displaying the receptor binding domain of SARS-CoV-2 elicit robust protective immune responses in rhesus monkeys
Bioconjug Chem. 2021 May 19;32(5):1034-1046.
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
J Biol Eng. 2021 Jun 29;15(1):18.
Establishing functional lentiviral vector production in a stirred bioreactor for CAR-T cell therapy
Bioengineered. 2021 Dec;12(1):2095-2105.
Mutation N501Y in RBD of spike protein strengthens the interaction between COVID-19 and its receptor ACE2
Biorxiv. 2021 February 18.
Screening and Identification of a Novel Anti-siglec-15 Human Antibody 3F1 and the Research on Its Antitumor Activity
Papers.SSRN. 2021 Oct.
An HIV-1 vaccine based on bacterium-like particles elicits Env-specific mucosal immune responses
Immunol Lett. 2020 Jun;222:29-39.
Establishing 293T suspension cultrue for lentiviral vector production in a stirred bioreactor
Authorea. 2020 November 10.

案例展示

HEK293瞬时转染培养基案例

支持高水平抗体瞬时表达
支持高水平病毒瞬时表达

OPM-CD Trans293 培养基支持重组蛋白或抗体的高水平瞬时表达，最高可达到1000mg/L以上

OPM-CD Trans293 培养基具有优异的批间稳定性

OPM-CD Trans293 培养基支持慢病毒（LV），腺病毒（AdV)以及腺相关病毒(AAV)的高水平瞬时表达。

OPM-CD Trans293+293 ProFeed 培养基与配套的293 ProFeed 补料可将病毒滴度提升50%以上，达到1x10⁷ TU/ml水平

使用 OPM-CD Trans293 培养基，得到的病毒滴度最高，工艺优化前即可达到2.29x10¹⁰ vg/ml水平。经过工艺优化，可以超过1x10¹¹ vg/ml

使用 OPM-CD Trans293 培养基，腺病毒滴度与某进口培养基一致（2x10⁹ IFU/mL）

常见问题

奥浦迈293瞬转的产量一般在多少？
- 一般抗体可以达到(50-300)mg/L。
在使用293 CD05产蛋白后，下游经常出现镍柱掉镍，蛋白不纯的情况，如何考虑改进？
- 可以建议客户使用耐受EDTA的镍柱，如GE 的Ni Excel。
OPM 293培养基可以用于细胞治疗领域吗？
- OPM 293-CD05搭配补料293-ProFeed，可以培养293FT细胞生产慢病毒（LV），慢病毒用于细胞治疗的载体。
293瞬转，客户使用补料293-ProFeed后细胞活率下降快？
- 需要摸索293-ProFeed的浓度，可以尝试分别补加5%，3%，7%。
奥浦迈培养基细菌内毒素控制在什么范围？
- （1)基础培养基控制在＜1.0 EU/ml，(2)补料控制在＜10 EU/ml，(3)超浓缩补料因为pH高，对内毒检测有干扰，所以一般只是作为内控，客户有要求的可以写在COA上，如CDFS08
奥浦迈对CD培养基的定义是什么，包括Insulin和IgF-1吗？
- 我们把胰岛素和IgF-1也定义为CD，但培养基里若含有这些成分，我们会明确告知客户。
补料中是否含有谷氨酰胺？
- 我们的补料中都不含谷氨酰胺；如含有谷氨酰胺，我们会标明。

商业化培养基

商业化培养基

01

02

03

04

05

Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2

Specificity of TGF-β1 signal designated by LRRC33 and integrin αVβ8

Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay

Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2

Specificity of TGF-β1 signal designated by LRRC33 and integrin αVβ8

Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay

A novel and secure pseudovirus reporter system based assay for neutralizing and enhancing antibody assay against Marburg virus

Anti-Claudin18. 2-IL-21 fusion protein bifunctional molecule has more powerful anti-tumor effect and better safety

Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity

Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2

Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells

Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo

Screening and Identification of a Novel Anti–Siglec-15 Human Antibody 3F1 and Relevant Antitumor Activity

Endodomain truncation of the HIV-1 envelope protein improves the packaging efficiency of pseudoviruses

Preclinical characterization of a Fab-like CD3/CLDN18. 2 XFab® bispecific antibody against solid tumors

Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain

Novel application of anti‐human Fc nanobody for screening high‐producing CHO cells for monoclonal antibody

ORF8 protein of SARS‐CoV‐2 reduces male fertility in mice

S373P Mutation of Spike Protein in SARS-CoV-2 Stabilizes Omicron

Augmenting Neutralization breadth against Diverse HIV-1 by increasing the Ab-Ag interface on V2

Structures of Omicron spike complexes and implications for neutralizing antibody development

Hemagglutinin‐based DNA vaccines containing trimeric self‐assembling nanoparticles confer protection against influenza

Screening of Monoclonal Antibodies Targeting the Equine IgG1 Based on Single B Cell Antibodies Gene Amplification Technology

Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine

S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates

An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope

Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD

Closed-state inactivation and pore-blocker modulation mechanisms of human CaV2. 2

N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2

Structure and Function of the Refined C-Terminal Loop in Imidazole Glycerol Phosphate Dehydratase from Different Homologs

Development of a tetravalent T-cell engaging bispecific antibody against glypican-3 for hepatocellular carcinoma

Self-assembling nanoparticle vaccines displaying the receptor binding domain of SARS-CoV-2 elicit robust protective immune responses in rhesus monkeys

Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds

Establishing functional lentiviral vector production in a stirred bioreactor for CAR-T cell therapy

Mutation N501Y in RBD of spike protein strengthens the interaction between COVID-19 and its receptor ACE2

Screening and Identification of a Novel Anti-siglec-15 Human Antibody 3F1 and the Research on Its Antitumor Activity

An HIV-1 vaccine based on bacterium-like particles elicits Env-specific mucosal immune responses

Establishing 293T suspension cultrue for lentiviral vector production in a stirred bioreactor

HEK293瞬时转染培养基案例

快速导航

联系我们

请扫描二维码关注奥浦迈官方公众号

申请新品试用